Medical device company Sensus Healthcare Inc (NASDAQ:SRTS) disclosed on Thursday the receipt of the 501(k) marketing clearance from the US Food and Drug Administration (FDA) for its new next-generation Superficial Radiation Therapy solution, SRT-100+, with immediate effect in the dermatology market.

The company said the SRT-100+ is the next-generation Superficial Radiation Therapy solution that adds several innovative features to its existing SRT-100 product.

According to the company, the additional features in the SRT-100+ include an expanded energy range for customized, more precise treatment, remote diagnostics, operation tracking, New X-ray tube with extended functionality and performance as well as advanced console and enhanced system mobility to optimize clinical practice

To date, SRT (superficial radiation therapy) technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. The SRT-100+ is used for treating non-melanoma skin cancer and keloids, concluded the company.